Abstract: The present disclosure relates to a fluidic device to detect, capture, and/or remove disease material in a biological fluid. The present invention also relates to methods for the treatment/prevention of sepsis through the use of the claimed device.

Abstract: Disclosed herein are analogues of 6-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidin-1 -yl)-[1,2,4]triazolo[4,3-b]pyridazine of formula (Ib), which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: The present disclosure provides for a device and method of control for an artificial prosthetic knee. A prosthetic knee according to the present disclosure relies on strictly passive means of providing support during weight bearing and supplements a resistive swing-phase mechanism with a small powered actuator. This actuator adds power to the knee, exclusively during swing phase, to improve swing-phase behavior. In particular, the knee still relies on the resistive swing-phase mechanism to provide nominal swing-phase knee motion, but supplements that motion as needed with the small powered actuator.

Abstract: A method for designing a patient-customized EA or selecting an existing EA that fits the patient best includes segmenting shapes of SOIs of the cochlea in a pre-operative CT image using a shape model; defining a 3D curve of interest within the shape model of the SOIs as a sequence of points-; automatically transforming the defined 3D curve to the pre-operative CT image so as to obtain a structure curve in the cochlea; determining a length and curvatures of the structure curve at the sequence of points; and designing a patient-customized EA or selecting an existing EA based on the determined length and curvatures of the structure curve such that after the EA shape model, which estimates the resting state shape of the EA, is rigidly registered to the structure curve in the cochlea, the EA shape model has a registration error smaller than a preset value.

Abstract: An exemplary robotic system includes a plurality of controllable joints and a controller. An exemplary control method provides for controlling the controllable joints by the controller. The control method provides for determining a configuration space for the robotic system and determining a reference movement path within the configuration space. The control method then provides for assigning a plurality of streamlines in the configuration space to yield a flow field based on the reference movement path. The control method then provides for measuring actual velocity vectors of the robotic system in the configuration space. The control method then provides for determining an error velocity vector based on a difference between the actual velocity vector and the desired velocity vector given by the flow field corresponding to the current robot configuration.

Abstract: In one aspect, the invention relates to binary compositions that disrupt ORco-mediated odorant sensing. In particular, compounds and compositions are provided that can inhibit sensory (e.g., host targeting) functions in organisms that express ORco receptors such as airborne insects, e.g., mosquitos, and ticks. Methods of employing such agents, and articles incorporating the same, are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Abstract: The present application provides a system and method for using a nuclear magnetic resonance (NMR) system. The method includes performing a pulse sequence using the NMR system that spatially encodes NMR signal evolutions to be acquired from a subject using an aggregated radio-frequency (B1) field incoherence and resolving the NMR signal evolutions acquired from the subject using at least one of a dictionary of known magnetic resonance fingerprinting (MRF) signal evolutions to determine matches in the NMR signal evolutions to the known MRF signal evolutions or an optimization process. The method also includes generating at least two spatially-resolved measurements indicating quantitative tissue parameters of the subject in at least two locations.

Abstract: The present disclosure is directed to the use of left-handed DNA (L-DNA) tracer to identify the source, track the distribution, and validate the integrity of products or resources that are highly regulated, valuable, or hazardous (e.g., pharmaceuticals, treated water, chemicals, designer products, and ammunitions). L-DNA tracers can encrypt unique identifying information, as well as more general information about the type of product, such as the manufacturing location, source, and date, directly into the nucleotide sequence. The L-DNA tracers can embed directly into the product so that it could neither be disassociated from the product nor be re-associated with another product. Because there are no technologies available to sequence L-DNA, the L-DNA tracers cannot be reverse engineered, copied, or falsified. The L-DNA tracers are only deciphered using a unique detection key.

Abstract: The present disclosure is directed to a cleavable agent for enhanced magnetic resonance generally corresponding to the formula Y-L-R, wherein Y represents a catalyst-binding moiety having at least one isotopically labeled heteroatom, L represents a cleavable bond, and R represents a hyperpolarized payload having at least one isotopically labeled carbon. Also disclosed herein is a method of cleaving the cleavable agent for enhanced magnetic resonance.

Abstract: The disclosure relates to genetically modified bacteria, genetically modified arthropods, and methods for controlling and/or reducing arthropod populations.

Abstract: Imaging methods for assessing the macromolecular content, such as myelin, are of great interest for understanding brain tissue microstructure, and have shown potentials in diagnosing and prognosing demyelinating diseases. for example. Magnetization transfer (MT) is a MRI contrast mechanism that enables detection of macromolecules. Previously, the MT effect has been analyzed by a semi-quantitative method termed magnetization transfer ratio (MTR) or by a quantitative magnetization transfer (qMT) method. However, because MTR does not have enough sensitivity and specificity to myelin, and qMT takes a very long scan time, their translation into clinical scenarios has been limited. This disclosure describes a MT data analysis metric using double saturation pulse offsets and powers (dopMTR).

Abstract: A nanotweezer and method of trapping and dynamic manipulation thereby are provided. The nanotweezer comprises a first metastructure including a first substrate, a first electrode, and a plurality of plasmonic nanostructures arranged in an array, and a trapping region laterally displaced from the array; a second metastructure including a second substrate and a second electrode; a microfluidic channel between the first metastructure and the second metastructure; a voltage source configured to selectively apply an electric field between the first electrode and the second electrode; and a light source configured to selectively apply an excitation light to the microfluidic channel at a first location corresponding to the array, thereby to trap a nanoparticle at a second location corresponding to the trapping region.

Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Abstract: Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure is directed towards systems and methods for detecting and sizing mineralized tissue. An exemplary method, according to an embodiment of the present disclosure, can provide for imaging a region of interest containing the mineralized tissue with unfocused ultrasound beams via a primary imaging method. The method can then provide for computing a wavefront coherence at the imaged region of interest. The method can then provide for segmenting pixels of the imaged region of interest based on their intensities and intensities of surrounding pixels. The method can then provide for identifying a border and a shadow of the mineralized tissue based on the segmenting. Then, the method can provide for calculating a size of the mineralized tissue based on the border and the shadow.

Abstract: A 2D spatial differentiator operates in transmission and comprises a Si nanorod photonic crystal that can transform an image, Ein, into its second-order derivative, Eout ? ?2 Ein, allowing for direct discrimination of the edges in the image. The use of a 2D photonic crystal allows for differentiation and edge detection in all directions with a numerical aperture (NA) up to 0.315 and an experimental resolution smaller than 4 ?m. The nanophotonic differentiator is able to be directly integrated into an optical microscope and onto a camera sensor, demonstrating the ease with which it can be vertically integrated into existing imaging systems. Furthermore, integration with a metalens is demonstrated for realizing a compact and monolithic image-processing system. In all cases, the use of the nanophotonic differentiator allows for a significant reduction in size compared to traditional systems, opening new doors for optical analog image processing in applications involving computer vision.

Abstract: This disclosure relates to a magnetorheological (MR) brake. The MR brake includes a rotor constructed at least partially of a ferromagnetic material, and a housing that supports the rotor such that the rotor and the housing are rotatable relative to each other about an axis, wherein the housing and rotor are configured such that a fluid gap is defined between the housing and the rotor, and wherein portions of the housing adjacent the rotor are constructed at least partially of a ferromagnetic material. An MR fluid is disposed in the fluid gap. A current-carrying coil is excitable to generate a magnetic field within ferromagnetic portions of the rotor and the housing and acts on the MR fluid. At least one element constructed of a material having low magnetic permeability is configured route the lines of magnetic flux through surrounding higher permeability material on opposite sides of the fluid gap.